P/E at 29.83 vs Industry's 37.46: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount to Industry Average

The current P/E ratio of 29.83 for Dr Reddys Laboratories Ltd represents a discount of approximately 20.4% relative to the sector average of 37.46. This valuation gap suggests the market is pricing in either subdued growth expectations or heightened risk factors compared to peers. Such a discount is significant in a sector where premium valuations often reflect strong pipeline prospects or robust earnings visibility. The stock’s mid-cap market capitalisation of ₹95,888.03 crores places it among sizeable players, yet the valuation gap raises questions about its comparative earnings quality or growth trajectory. What factors are driving this valuation divergence despite the sector’s overall strength?

Performance Across Timeframes: Divergent Momentum

Examining the stock’s price performance reveals a nuanced picture. Over the past year, Dr Reddys Laboratories Ltd has declined by 11.18%, underperforming the Sensex’s 7.46% fall. However, the one-month and one-week returns of -1.98% and -1.05% respectively, while negative, are less severe than the Sensex’s declines of -4.40% and -1.99%. This suggests some relative resilience in the short term. Contrastingly, the three-month return of -9.45% starkly contrasts with the Sensex’s positive 1.53%, indicating a recent acceleration in underperformance. The year-to-date return of -9.62% is marginally better than the Sensex’s -11.94%, hinting at some recovery earlier in the year that has since faltered. Is this recent weakness a temporary setback or indicative of deeper challenges?

Moving Average Configuration: Bearish Technical Setup

The technical picture for Dr Reddys Laboratories Ltd is decidedly bearish. The stock is trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling sustained downward pressure. This configuration typically reflects a lack of short-term momentum and a longer-term downtrend. The absence of any recent bounce above short-term averages suggests that attempts at recovery have been weak or short-lived. Given the high intraday volatility of 39.86% observed recently, the stock is experiencing significant price swings, but these have not translated into a sustained upward trend. Could this be a consolidation phase before a trend reversal, or is the downtrend set to continue?

Relative Sector Performance: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen mixed results in recent earnings announcements. Out of 34 stocks that have declared results, 14 reported positive outcomes, 15 were flat, and 5 posted negative results. This distribution indicates a broadly stable sector environment with pockets of strength and weakness. How does Dr Reddys Laboratories Ltd compare to its peers in terms of earnings momentum and valuation? The stock’s underperformance relative to the sector average P/E and recent price trends suggests it may be lagging behind some competitors despite the sector’s overall resilience.

Rating Context: Previously Rated Hold, Now Reassessed

MarketsMOJO had previously assigned a Hold rating to Dr Reddys Laboratories Ltd, with a Mojo Score of 30.0. The rating was updated on 13 Jul 2026, reflecting changes in the company’s fundamentals and market conditions. The reassessment coincides with the stock’s valuation discount and recent underperformance, as well as its technical weakness. What is the current rating, and how does it factor in the valuation premium and technical signals?

Longer-Term Performance: Lagging Behind the Sensex

Over extended periods, Dr Reddys Laboratories Ltd has underperformed the broader market. The three-year return stands at 2.90%, significantly below the Sensex’s 12.69%. Similarly, the five-year return of 16.88% trails the Sensex’s 28.72%, and the ten-year return of 79.90% is less than half the Sensex’s 160.61%. This persistent underperformance over multiple time horizons highlights challenges in sustaining growth or market leadership. The stock’s current valuation discount may partly reflect this historical trend. Should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Intraday Volatility and Trading Range

On the trading day of 9 Sep 2026, Dr Reddys Laboratories Ltd exhibited high intraday volatility of 39.86%, with a narrow trading range of ₹6.25. Despite this volatility, the stock underperformed its sector by 0.43%, declining 0.23% compared to the Sensex’s 0.70% fall. Such volatility combined with a narrow price range may indicate indecision among market participants or the presence of significant support and resistance levels. The persistent trading below all major moving averages further emphasises the technical challenges facing the stock.

Summary: What the Data Collectively Shows

The data on Dr Reddys Laboratories Ltd paints a picture of a stock trading at a meaningful valuation discount to its sector, yet struggling with recent and longer-term underperformance. The bearish moving average configuration and high intraday volatility underscore technical weakness, while the mixed sector results suggest the company is not fully aligned with broader industry trends. The reassessment of its rating from Hold reflects these complexities. How will the current rating incorporate these valuation, performance, and technical factors?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →